A Phase 1 interventional study of Vyxeos and Venetoclax in Leukemia, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 1 site in United States. Open to participants aged 1 Year to 39 Years. Per ClinicalTrials.gov, last updated 2026-02-18.
Sponsored by Children's Hospital Medical Center, Cincinnati · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing venetoclax in Leukemia — 16 open to participants now, 20 under way, 3 of them phase 3. venetoclax · Leukemia.
Among the 29 studies testing venetoclax in Leukemia, this one is the 22nd largest by planned enrollment, is one of 3 that started in 2018, is one of 7 in phase 1, reaches primary completion later than 6 of the 19 other live ones, and was the 8th registered.
2,382 studies on the registry are indexed under Leukemia; 252 are open to participants now.
Browse Leukemia studies →16 of the 29 studies testing venetoclax in Leukemia are open now, in 12 countries. Recruiting first, the newest first:
Jacqueline Garcia, MD · Sites in United States
Ages 18–90
The Methodist Hospital Research Institute · Sites in United States
Ages 18+
Jacqueline Garcia, MD · Sites in United States
Ages 18+
Princess Maxima Center for Pediatric Oncology · Sites in Austria, Belgium, Denmark and 11 more countries
Ages 1–21
Princess Maxima Center for Pediatric Oncology · Sites in Austria, Belgium, Denmark and 11 more countries
Ages 1–21
By country, each count listing its studies:
venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 206 Leukemia studies recruiting now, 111 (54%) set no upper age limit and 74 (36%) stop at 75 or younger; 85 take children under 18; 24 take healthy volunteers.
This study: 1 Year to 39 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 17 · Phase 3 4
First in 2016; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 21 is below the median of 40 across 1,770 interventional studies indexed under Leukemia.
Median enrollment 42 across the 29 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 29 have an industry lead sponsor. The 10 most frequent:
Children's Hospital Medical Center, Cincinnati is the lead sponsor of 673 studies on the registry; 129 are open to participants now.
Of its 57 completed or terminated interventional studies of FDA-regulated products, 32 (56%) have results posted.
Children's Hospital Medical Center, Cincinnati has 4 studies filed under Leukemia — fewer than ten, so there is no comparison to draw.
7 of the studies testing venetoclax in Leukemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT06152809Dana-Farber Cancer InstituteCIML NK Cells With Venetoclax for AML | 2026-11-30 |
| NCT03467867Georgetown UniversityA Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL | 2026-12 |
| NCT07044544University of Alabama at BirminghamTrial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies | 2026-12 |
| NCT06429449University of Colorado, DenverMitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia | 2026-12 |
Add all 7 to your calendar (.ics) → With an account.
Among the 29 studies testing venetoclax in Leukemia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the safety and tolerability of combining venetoclax with Vyxeos (CPX-351) in pediatric and young adult patients with acute leukemia that has come back or not responded to treatment.
This is a single-institution Phase I pilot study designed to test the safety and tolerability of combining venetoclax with Vyxeos (CPX-351, cytarabine and daunorubicin liposome) for the treatment of relapsed/refractory acute leukemia in young patients. Subjects will receive a single course of study therapy consisting of daily, oral or crushed venetoclax at an assigned dose level with a 3-day ramp-up to target dose and Vyxeos administered intravenously at the established dose on Days 1, 3, and 5. In addition to safety and tolerability, the overall response rate to these therapies will be estimated. Pharmacokinetic (PK) analysis will also be conducted to define the drug clearance of venetoclax in this combination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of one of the following:
Acute myeloid leukemia (AML), any subtype except
Acute leukemia of ambiguous lineage (ALAL)
Disease Status
Prior therapy requirements
Exclusion Criteria:
Diagnosis of one of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Venetoclax will be given orally on Days per the assigned dose level. A single course consisting of 3 doses of Vyxeos and 7-21 doses of venetoclax depending on the assigned dose level will be administered to participants in this study. Vyxeos will be administered by central venous catheter over 90 minutes on Day 1, 3, and 5. Venetoclax is given daily by mouth per assigned dose level.
Drug: Vyxeos · Drug: Venetoclax
Vyxeos Dose: daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 administered via intravenous infusion over 90 minutes on Days 1, 3, and 5.
Also known as: cytarabine and daunorubicin liposome, CPX-351
Venetoclax Dose: 1. Dose Level 0 - weight based daily dosing for 21 days 2. Dose Level -1 - weight based daily dosing for 14 days 3. Dose Level -2- weight based daily dosing for 10 days 4. Dose Level -3- weight based daily dosing for 7 days
Also known as: Venclexta
Feasibility of combining venetoclax and Vyxeos (dose limiting toxicities)
If 2 or more participants have dose limiting toxicities at a given dose level, the maximum tolerated dose will have been exceeded.
Time frame: 28 days
Treatment related toxicities
Number of related adverse events
Time frame: 60 days
Disease response
Estimate of overall response rate (ORR) defined as (CR/CRi/CRp).
Time frame: 42 days
Cancer therapeutics-related cardiac dysfunction (CTRCD) in patients who have previously received anthracyclines
Measured by echocardiogram (ECHO)
Time frame: 60 days
Plan to share: No
Started Dec 2018 (actual). Primary completion is estimated for Jan 2027, 97 months after the start.
Of 112 non-industry phase 1 interventional studies under Leukemia, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 88. This study's planned 97 months is above that.
Counting every sponsor, half of 162 studies reached it within 53 months; a quarter within 34 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: CPX-351 · Venetoclax
Children's Hospital Medical Center, Cincinnati →